| Literature DB >> 35456353 |
Kasper Møller Boje Rasmussen1,2, Niels Cramer West1,2, Michael Bille1, Matilde Grønborg Sandvej1, Per Cayé-Thomasen1,2.
Abstract
Cochlear implantation is considered the best treatment option for patients with severe-to-profound sensorineural hearing loss for whom conventional hearing aids are insufficient. We used a repeated measures longitudinal approach to evaluate speech recognition and patient-reported outcomes after cochlear implantation in an unbiased cohort of Danish adult patients in a prospective cohort study. We assessed 39 recipients before and two times after implantation using a battery of tests that included Dantale I, the Danish Hearing in Noise Test, the Nijmegen Cochlear Implant Questionnaire, and the Speech, Spatial, and Qualities of Hearing Scale. The study group improved significantly on all outcome measures following implantation. On average, Dantale I scores improved by 29 percentage points and Hearing in Noise Test scores improved by 22 percentage points. Most notably, the average Dantale score improved from 26 to 70% in the CI in quiet condition and from 12 to 42% in the cochlear implantation in noise condition when tested monaurally. Dantale demonstrated a significant positive correlation with Nijmegen Cochlear Implant Questionnaire and Speech, Spatial, and Qualities of Hearing Scale scores, while Hearing in Noise Test had no significant correlation with the patient-reported outcome measures. Patients improved significantly at 4 months and marginally improved further at 14 months, indicating that they were approaching a plateau. Our study's use of audiometric and patient-reported outcome measures provides evidence of the treatment benefits of cochlear implantation in adults, which may help physicians advise patients on treatment decisions and align treatment benefit expectations, as well as serve as a foundation for the development of new cochlear implantation selection criteria.Entities:
Keywords: PROM; cochlear implant; hearing loss; hearing rehabilitation; outcome; patient-reported outcome measures; treatment
Year: 2022 PMID: 35456353 PMCID: PMC9032498 DOI: 10.3390/jcm11082257
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Demographic characteristics of the 39 study patients.
| Age at Implantation | 28–90 Years (Mean 64) |
|---|---|
| Gender | 15 females (38%), 24 males (62%) |
| Implanted side | 23 left (59%), 16 right (41%) |
| Duration of hearing aids | |
| CI ear | 18 years (range 0–57 years) |
| Contralateral ear | 19 years (range 0–57 years) |
| Hearing loss degree | |
| CI ear | |
| Moderate–severe (56–90 dB) | 24 (62%) |
| Profound (91+ dB) | 15 (38%) |
| Contralateral ear | |
| Moderate–severe (56–90 dB) | 31 (79%) |
| Profound (91+ dB) | 8 (21%) |
| Type of implant | 1 (3%) Advanced Bionics HiRes Ultra 3D SlimJ |
| 2 (5%) Advanced Bionics HiRes90K Midscale | |
| 3 (8%) Advanced Bionics ULTRA 3D Midscale | |
| 1 (3%) MED-EL Flex 28 Synchrony | |
| 22 (56%) Nucleus Cochlear CI522 | |
| 6 (13%) Nucleus Cochlear CI622 | |
| 4 (10%) Oticon Medical Zti EVO | |
| Audiometric test—days after implantation | |
| T1 | 235 days, 110–330 (mean, range) ~ 8 months |
| T2 | 440 days, 343–636 (mean, range) ~ 15 months |
| PROMs—days after implantation | |
| T1 | 124 days, 66–241 (mean, range) ~ 4 months |
| T2 | 426 days, 301–569 (mean, range) ~ 14 months |
The baseline info on hearing loss etiology and pre-operative hearing for the 39 included patients.
| ID | Etiology | Gender | Age | PTA6 | PTA6 | SRS | SRS |
|---|---|---|---|---|---|---|---|
| (Years) | (dB HL) | (dB HL) | (%) | (%) | |||
| 1 | Ménière’s disease | M | 77 | 77 | 52 | 45 | 80 |
| 2 | Otitis media | M | 73 | 110 | 106 | 9 | 53 |
| 3 | Otosclerosis | F | 53 | 120 | 78 | 0 | 68 |
| 4 | Congenital (unknown etiology) | F | 46 | 108 | 115 | 0 | 0 |
| 5 | Unknown | M | 70 | 98 | 70 | 0 | 28 |
| 6 | Unknown | M | 74 | 98 | 86 | 48 | 33 |
| 7 | Late-onset progressive hereditary | F | 69 | 77 | 83 | 60 | 60 |
| 8 | Superficial Siderosis | F | 67 | 68 | 59 | 24 | 24 |
| 9 | Late-onset progressive hereditary | M | 69 | 87 | 89 | 24 | 32 |
| 10 | Hereditary congenital | M | 69 | 111 | 90 | 0 | 45 |
| 11 | Unknown | M | 81 | 78 | 69 | 14 | 56 |
| 12 | Unknown | M | 70 | 108 | 78 | 0 | 85 |
| 13 | Usher syndrome | F | 60 | 92 | 86 | 50 | 68 |
| 14 | Late-onset progressive hereditary | F | 62 | 76 | 71 | 29 | 28 |
| 15 | Late-onset progressive hereditary | M | 60 | 75 | 78 | 45 | 55 |
| 16 | Unknown | F | 75 | 103 | 82 | 0 | 9 |
| 17 | Late-onset progressive hereditary | M | 59 | 108 | 108 | 0 | 0 |
| 18 | Unknown | M | 88 | 67 | 64 | 56 | 49 |
| 19 | Ototoxicity | F | 90 | 79 | 77 | 0 | 0 |
| 20 | Unknown | M | 74 | 75 | 63 | 14 | 21 |
| 21 | Late-onset progressive hereditary | M | 80 | 63 | 55 | 20 | 35 |
| 22 | Unknown | M | 73 | 78 | 77 | 39 | 28 |
| 23 | Unknown | M | 56 | 99 | 74 | 0 | 77 |
| 24 | Neurofibromatosis | M | 56 | 68 | 72 | 15 | 35 |
| 25 | Congenital (unknown etiology) | M | 53 | 103 | 84 | 35 | 85 |
| 26 | Vestibular schwannoma | M | 75 | 83 | 118 | 50 | 0 |
| 27 | Pendred syndrome | F | 28 | 84 | 70 | 33 | 70 |
| 28 | Hereditary congenital | F | 43 | 96 | 87 | 48 | 60 |
| 29 | Unknown | F | 40 | 86 | 118 | 40 | 0 |
| 30 | Late-onset progressive hereditary | M | 72 | 78 | 74 | 35 | 65 |
| 31 | Unknown | F | 85 | 115 | 82 | 0 | 10 |
| 32 | Unknown | F | 30 | 88 | 63 | 31 | 68 |
| 33 | Otosclerosis | M | 81 | 88 | 86 | 20 | 30 |
| 34 | Pneumococcal meningitis | M | 69 | 56 | 53 | 30 | 40 |
| 35 | Late-onset progressive hereditary | M | 87 | 79 | 59 | 55 | 40 |
| 39 | Unknown | F | 38 | 73 | 118 | 75 | 0 |
| 40 | Unknown | M | 79 | 73 | 67 | 41 | 68 |
| 42 | Late-onset progressive hereditary | F | 36 | 73 | 68 | 78 | 72 |
| 43 | Hereditary congenital | M | 33 | 104 | 91 | 8 | 40 |
F: female; M: male; PTA6: pure-tone average of frequencies 0.25, 0.5, 1, 2, 4, 8 kHz (headphone based); SRS, speech recognition score (in a quiet setting at individually determined most comfortable loudness levels using headphones).
Individual patient outcomes for audiometric test measures (Dantale I and HINT) and patient-reported outcome measures (NCIQ and SSQ) at T0/T1/T2.
| ID | Dantale I | HINT | NCIQ | SSQ | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Best Aided with Lipreading | Best Aided in Quiet without Lipreading | Best Aided in Noise without Lipreading | CI Ear in Quiet | CI Ear in Noise | HINT-Q: Sentences | HINT-Q: Words | HINT-N: Sentences | HINT-N: Words | |||
| (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | Total Score | Total Score | |
| 1 | 85/94/89 | 85/89/84 | 51/43/60 | 46/53/51 | 29/21/38 | 50/75/100 | 80/92/100 | 35/68/80 | 62/79/88 | 257/293/265 | NA/42/42 |
| 2 | 86/98/90 | 65/81/88 | 28/49/54 | NA/81/76 | NA/45/54 | 45/85/90 | 69/96/98 | 15/45/70 | 18/67/78 | 232/268/273 | 30/37/32 |
| 3 | 59/94/91 | 34/91/96 | 21/53/59 | NA/71/76 | NA/44/59 | NA/95/100 | NA/98/100 | NA/60/80 | NA/83/90 | 239/289/377 | 27/34/NA |
| 4 | 40/63/86 | 2/44/59 | NA/NA/NA | 2/44/59 | NA/NA/NA | NA/NA/NA | NA/NA/NA | NA/NA/NA | NA/NA/NA | 329/323/348 | 25/16/47 |
| 5 | 41/94/99 | 31/88/96 | NA/49/55 | 9/71/88 | NA/49/55 | NA/95/80 | NA/98/91 | NA/65/90 | NA/83/96 | 246/448/487 | 26/77/84 |
| 6 | 86/86/84 | 49/75/78 | NA/19/33 | 8/48/58 | NA/19/33 | 10/NA/65 | 28/NA/87 | NA/NA/20 | 8/NA/44 | 263/425/410 | 23/50/56 |
| 7 | NA/98/96 | 45/93/83 | 40/71/74 | 45/91/83 | 36/65/74 | 70/95/90 | 86/99/98 | 35/75/80 | 63/91/93 | 377/423/435 | 64/57/62 |
| 8 | 88/79/84 | 78/46/65 | 30/30/21 | 48/46/65 | NA/30/21 | 35/20/20 | 46/33/33 | 15/NA/NA | 33/NA/NA | 171/248/185 | 5/20/5 |
| 9 | 70/86/94 | 30/76/78 | 10/36/14 | 16/73/78 | 4/36/14 | NA/60/60 | NA/78/80 | NA/25/40 | NA/56/65 | 253/418/403 | 39/65/59 |
| 10 | 62/93/90 | 34/68/75 | 3/58/53 | NA/68/75 | NA/58/53 | NA/20/40 | 14/42/68 | NA/10/20 | NA/34/51 | 486/533/533 | 54/90/74 |
| 11 | 84/99/99 | 75/91/95 | 64/54/54 | 29/74/90 | 26/40/53 | NA/NA/NA | NA/NA/NA | NA/NA/NA | NA/NA/NA | 266/412/328 | 27/56/42 |
| 12 | 89/98/96 | 77/88/89 | 36/58/55 | 35/88/86 | NA/56/55 | 70/100/100 | 92/100/100 | 60/75/80 | 81/91/92 | 234/328/315 | 18/31/41 |
| 13 | 86/94/95 | 63/91/88 | 24/36/39 | 18/74/79 | 18/36/30 | 55/100/100 | 80/100/100 | 55/75/85 | 73/84/96 | 373/487/NA | 46/72/74 |
| 14 | 66/88/98 | 70/93/91 | 27/60/63 | 70/86/81 | 27/60/55 | 60/90/95 | 80/96/99 | 30/60/65 | 61/76/84 | 293/434/447 | 16/57/37 |
| 15 | 92/100/99 | 69/83/89 | 21/64/69 | 36/83/89 | 13/64/69 | 75/100/85 | 88/100/95 | 45/70/60 | 65/82/78 | 240/385/425 | 20/58/90 |
| 16 | 38/53/61 | 8/40/54 | NA/5/4 | 1/28/26 | NA/5/NA | NA/NA/5 | NA/NA/22 | NA/NA/NA | NA/NA/NA | NA/226/NA | NA/NA/NA |
| 17 | 58/NA/63 | 28/NA/21 | NA/NA/1 | 10/NA/15 | NA/NA/1 | NA/NA/NA | 5/NA/NA | NA/NA/NA | NA/NA/NA | 261/341/NA | 29/9/NA |
| 18 | 83/88/NA | 66/85/85 | 14/44/51 | 40/69/73 | 6/33/41 | NA/NA/NA | NA/NA/NA | NA/NA/NA | NA/NA/NA | 373/508/549 | 32/71/71 |
| 19 | 26/76/84 | 7/73/76 | NA/NA/11 | NA/65/76 | NA/NA/NA | NA/NA/NA | NA/NA/NA | NA/NA/NA | NA/NA/NA | 256/341/364 | 17/45/NA |
| 20 | 57/88/86 | 39/66/74 | 15/30/30 | 9/46/45 | 4/19/28 | NA/NA/NA | NA/NA/NA | NA/NA/NA | NA/NA/NA | 311/355/360 | 16/25/NA |
| 21 | 94/96/91 | 70/84/80 | 21/43/45 | 31/84/68 | 3/43/33 | 95/90/85 | 99/98/93 | 80/85/75 | 91/93/88 | 325/396/368 | 52/56/72 |
| 22 | 79/96/95 | 65/98/94 | 13/73/69 | 23/98/88 | 13/73/61 | 40/85/NA | 74/96/NA | 40/NA/NA | 64/NA/NA | 444/547/532 | 66/64/NA |
| 23 | 89/98/98 | 61/96/93 | 31/49/68 | NA/78/90 | NA/49/59 | 85/100/NA | 95/100/NA | 35/90/NA | 61/98/NA | 238/308/NA | 19/16/NA |
| 24 | 65/88/85 | 59/81/78 | 14/38/36 | NA/81/78 | NA/38/36 | NA/84/75 | NA/94/93 | NA/49/65 | NA/65/87 | 259/371/404 | 9/19/NA |
| 25 | 87/100/96 | 70/81/91 | 44/60/54 | NA/61/73 | NA/31/26 | 35/70/85 | 59/86/93 | 40/40/15 | 56/66/44 | 310/414/433 | 38/49/69 |
| 26 | 40/75/86 | 29/84/84 | 8/46/55 | 29/84/84 | 8/46/55 | NA/70/75 | NA/85/90 | NA/20/50 | NA/42/72 | 340/339/374 | 32/16/40 |
| 27 | 88/93/91 | 74/89/95 | 40/75/45 | 41/68/69 | 11/33/44 | 50/65/80 | 72/87/89 | 15/45/60 | 42/78/78 | 384/461/478 | 47/99/NA |
| 28 | 88/96/99 | 79/98/91 | 20/66/73 | 33/91/88 | 16/66/73 | 75/80/100 | 85/95/100 | 20/93/90 | 47/80/92 | 332/526/529 | 18/74/60 |
| 29 | 39/83/93 | 34/54/69 | 16/30/51 | NA/54/69 | NA/30/51 | NA/5/15 | NA/35/54 | NA/NA/NA | NA/NA/21 | 177/239/291 | 9/NA/19 |
| 30 | 73/NA/96 | 64/91/93 | 24/85/63 | 41/85/89 | 4/85/63 | 80/85/100 | 90/99/100 | 75/80/90 | 80/94/98 | 340/487/432 | 24/73/51 |
| 31 | 20/48/69 | 6/23/33 | NA/NA/NA | NA/23/33 | NA/NA/NA | NA/NA/NA | NA/NA/NA | NA/NA/NA | NA/NA/NA | 315/384/332 | 24/19/22 |
| 32 | 70/93/98 | 49/75/90 | 46/28/49 | NA/75/85 | NA/28/49 | 30/95/95 | 74/95/99 | 15/45/90 | 63/66/98 | 206/385/474 | 18/35/66 |
| 33 | 85/96/90 | 58/74/73 | 29/43/41 | NA/65/73 | NA/43/30 | NA/78/85 | NA/87/90 | NA/60/35 | NA/88/61 | 194/495/421 | 7/86/52 |
| 34 | 52/53/64 | 50/40/30 | 45/45/24 | 25/40/30 | 16/45/24 | NA/NA/NA | 9/15/NA | NA/NA/NA | NA/NA/NA | 288/287/304 | 29/34/26 |
| 35 | 43/65/69 | 23/48/41 | 10/18/1 | 10/44/31 | 8/18/NA | NA/NA/NA | NA/NA/NA | NA/NA/NA | NA/NA/NA | 235/308/290 | 19/31/18 |
| 39 | 74/79/90 | 74/79/81 | 44/45/39 | 74/79/81 | 44/45/39 | 55/25/30 | 80/71/67 | 55/5/NA | 73/35/35 | 210/355/351 | 21/51/76 |
| 40 | 70/58/80 | 56/53/69 | 17/30/16 | 19/43/64 | 15/30/14 | 40/75/NA | 65/86/NA | 25/35/NA | 50/65/NA | 242/329/308 | 20/15/40 |
| 42 | 85/98/100 | 72/94/95 | 42/70/74 | 57/86/86 | 36/70/68 | 35/NA/NA | 65/NA/NA | 20/NA/NA | 54/NA/NA | 322/NA/NA | 40/50/NA |
| 43 | 58/86/85 | 59/88/91 | 10/53/69 | 19/63/73 | NA/46/55 | 10/NA/NA | 41/NA/NA | NA/NA/NA | 16/NA/NA | 328/418/NA | 2/41/NA |
Test scores for all patients enrolled presented as T0/T1/T2; HINT: Hearing in Noise Test; NCIQ: Nijmegen Cochlear Implant Questionnaire; SSQ: Speech, Spatial, and Qualities of Hearing Scale; NA: Not available.
Summary of audiometric data showing significant improvements between the evaluation time points T0 (baseline), T1, and T2 (post-implantation) using a repeated measures ANOVA. Mean difference between T0 and T2, as well as p values end effect sizes () are reported.
|
| T0 | T1 | T2 | Mean Difference (T0–T2) a |
| |||
|---|---|---|---|---|---|---|---|---|
| Dantale | ||||||||
| Best aided with lipreading | (%) | 35 | 68 (61–75) | 85 (80–90) | 89 (85–92) | 21 (13–28) | <0.001 | 0.588 |
| Best aided in quiet without lipreading | (%) | 38 | 52 (45–60) | 76 (70–82) | 79 (74–85) | 27 (19–35) | <0.001 | 0.667 |
| Best aided in noise without lipreading | (%) | 36 | 24 (18–29) | 46 (40–52) | 46 (39–53) | 22 (13–31) | <0.001 | 0.516 |
| CI ear in quiet | (%) | 31 | 26 (18–34) | 66 (59–74) | 70 (62–77) | 43 (33–53) | <0.001 | 0.794 |
| CI ear in noise | (%) | 31 | 12 (7–16) | 42 (34–50) | 42 (33–50) | 30 (20–40) | <0.001 | 0.663 |
| HINT | ||||||||
| HINT-Q: sentences | (%) | 16 | 55 (43–67) | 75 (60–90) | 81 (67–95) | 26 (9–43) | <0.001 | 0.528 |
| HINT-Q: words | (%) | 16 | 75 (64–86) | 87 (76–98) | 90 (80–99) | 15 (3–26) | 0.003 | 0.446 |
| HINT-N: sentences | (%) | 15 | 38 (25–51) | 58 (44–72) | 64 (48–80) | 26 (1–50) | 0.012 | 0.370 |
| HINT-N: words | (%) | 15 | 58 (45–72) | 74 (64–85) | 80 (68–91) | 21 (4–39) | 0.006 | 0.432 |
Test scores are presented as means and 95% confidence interval in parantheses; CI: cochlear implant; HINT: Hearing in Noise test. a Bonferroni adjusted pairwise comparison between T0 and T2.
Figure 1Scores in five Dantale and four HINT conditions at different time points (T0, T1, and T2) of the patient cohort (n = 39) are represented in box plots. Columns present means and whiskers present 95% confidence intervals.
Summary of patient-reported outcome measures showing significant improvements between the evaluation time points T0 (baseline), T1, and T2 (post-implantation) using a Wilcoxon signed rank test. Z-statistics and p values are reported.
| T0 | T1 | T2 | Wilcoxon Signed Rank Test | ||||
|---|---|---|---|---|---|---|---|
| T0–T1 | T0–T2 | ||||||
| Z | Z | ||||||
| NCIQ total score | 264 (239–330) | 384 (324–437) | 377 (321–441) | −5.2 | <0.001 | −5.0 | <0.001 |
| Physical subdomains | |||||||
| Basic sound perception | 35 (28–51) | 63 (49–78) | 63 (60–72) | −5.2 | <0.001 | −4.9 | <0.001 |
| Advanced sound perception | 38 (28–53) | 56 (40–71) | 58 (44–74) | −4.8 | <0.001 | −4.4 | <0.001 |
| Speech production | 68 (58–85) | 75 (64–90) | 78 (65–86) | −2.6 | 0.009 | −2.1 | 0.024 |
| Psychological subdomain | |||||||
| Self-esteem | 45 (33–58) | 61 (48–76) | 58 (50–74) | −4.5 | <0.001 | −4.1 | <0.001 |
| Social subdomains | |||||||
| Activity limitations | 45 (37–53) | 67 (54–80) | 67 (52–77) | −5.2 | <0.001 | −4.8 | <0.001 |
| Social interactions | 50 (33–60) | 69 (53–78) | 65 (50–79) | −4.8 | <0.001 | −4.7 | <0.001 |
| SSQ total score | 24 (18–35) | 47 (23–64) | 51 (37–70) | −3.7 | <0.001 | −4.1 | <0.001 |
| Speech | 7 (4–14) | 15 (8–26) | 18 (10–26) | −4.4 | <0.001 | −4.4 | <0.001 |
| Spatial | 6 (3–10) | 12 (6–17) | 11 (7–21) | −3.6 | <0.001 | −3.2 | 0.002 |
| Qualities | 10 (6–16) | 22 (9–25) | 20 (15–29) | −2.9 | 0.004 | −4.0 | <0.001 |
Test scores are presented as medians and 25th and 75th percentiles in parentheses; NCIQ, Nijmegen Cochlear Implant Questionnaire; SSQ, Speech, Spatial, and Qualities of Hearing Scale.
Figure 2Subdomain percentile scores for the Nijmegen Cochlear Implant Questionnaire (NCIQ) and the Speech, Spatial, and Qualities of Hearing Scale (SSQ) at T0, T1 and T2. Boxes present the median and the 25th and 75th percentiles. Whiskers present the maximum and minimum values. Total scores are presented on the right y axis.
Correlations between audiometric and patient-reported outcome measures at the second post-implantation follow-up (T2) using Spearman coefficients.
| Dantale | HINT | |||||||
|---|---|---|---|---|---|---|---|---|
| Test Condition | Best Aided in Quiet without Lipreading | Best Aided in Noise without Lipreading | CI Ear in Quiet | CI Ear in Noise | HINT-Q: Sentences | HINT-Q: Words | HINT-N: Sentences | HINT-N: Words |
| NCIQ total score | 0.53 *** | 0.44 ** | 0.48 ** | 0.47 ** | 0.15 | 0.13 | 0.21 | 0.26 |
| SSQ total score | 0.45 * | 0.30 | 0.45 * | 0.32 | −0.02 | 0.02 | 0.07 | 0.12 |
CI: cochlear implant; HINT-Q/N: Hearing in noise test quiet/noise; NCIQ: Nijmegen cochlear implant questionnaire; SSQ: Speech, spatial, and qualities of hearing. * p < 0.05; ** p < 0.01; *** p < 0.001.